Primary IgAN research hub

A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)

This phase III clinical trial tests a medicine called atrasentan in children and teenagers aged 2 to 17 who have IgA nephropathy, a kidney condition. Researchers want to see if the drug safely lowers the amount of protein leaking into the urine, which helps protect kidney health.